GlucoTrack, Inc. (NASDAQ:GCTK) Short Interest Up 634.6% in January

GlucoTrack, Inc. (NASDAQ:GCTK) saw a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 234,255 shares, a growth of 634.6% from the January 15th total of 31,889 shares. Approximately 23.3% of the shares of the company are short sold. Based on an average daily volume of 1,698,025 shares, the days-to-cover ratio is presently 0.1 days. Based on an average daily volume of 1,698,025 shares, the days-to-cover ratio is presently 0.1 days. Approximately 23.3% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of GlucoTrack in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Trading of GlucoTrack

A hedge fund recently raised its stake in GlucoTrack stock. Bank of America Corp DE grew its holdings in shares of GlucoTrack, Inc. (NASDAQ:GCTK) by 102,125.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 4,089 shares of the company’s stock after acquiring an additional 4,085 shares during the quarter. Bank of America Corp DE owned about 0.85% of GlucoTrack worth $25,000 as of its most recent SEC filing. Institutional investors own 10.92% of the company’s stock.

GlucoTrack Stock Performance

GlucoTrack stock traded up $0.04 during midday trading on Tuesday, reaching $1.79. 52,506 shares of the stock traded hands, compared to its average volume of 949,163. The firm has a fifty day moving average price of $3.93 and a two-hundred day moving average price of $5.32. GlucoTrack has a fifty-two week low of $1.52 and a fifty-two week high of $40.78. The firm has a market cap of $1.81 million, a price-to-earnings ratio of -0.05 and a beta of 0.32. The company has a current ratio of 1.53, a quick ratio of 1.53 and a debt-to-equity ratio of 0.08.

About GlucoTrack

GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.